secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2024-09-13T23:59:59+00:00
Accession:  0001193125-24-218879
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Reneo Pharma terminates CDO Ashley Hall amid planned merger with OnKure
-----------------------------------------------------------------------

- Ashley F. Hall, Chief Development Officer, terminated effective Sept 13, 2024.
- Termination linked to planned merger with OnKure, Inc. and cessation of drug development.
- Hall will receive severance benefits under previously disclosed severance plan.
- Merger with OnKure is expected to shift company away from historical drug development.
- Gregory J. Flesher remains CEO; no replacement for CDO announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000119312524218879/0001193125-24-218879-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000119312524218879/d809509d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-218879

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer